Robert Crane

i-STAT Corp. is used to develope, manufacture and market medical diagnostic products for blood analysis that provide healthcare professionals critical diagnostic information accurately and immediately at the point of patient care. Founded in 1983 by Imants Lauks, i-STAT was headquartered in East Windsor, NJ.

Inkine Pharmaceutical Co., Inc. develops pharmaceutical products. The firm's products include Visicol(R) and IBStat(R). Its products are used for diagnosis and treatment of gastrointestinal disorders. The company was founded by Leonard S. Jacob in 1970 and is headquartered in Blue Bell, PA.

Part of Ligand Pharmaceuticals, Inc., Seragen, Inc. develops drugs. The company is based in Westerly, RI. Seragen was acquired by Ligand Pharmaceuticals, Inc. on August 12, 1998 for $57.96 million.

CB Biomedical, Inc. develops and produces novel bioartificial organs based on proprietary mammalian cell and semi permeable membrane technologies. The company is headquartered in Lexington, MA

GI Dynamics, Inc. engages in the development and commercialization of a medical device system intended for treatment of patients with type 2 diabetes and reduction of obesity. Its pipeline product is EndoBarrier, an endoscopically delivered medical device intended to help restore healthy blood sugar levels and reduce weight. The company was founded by Andy Levine on March 24, 2003 and is headquartered in Boston, MA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.